Сравнение

Buserelin vs. Linaclotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

57982-77-1

851199-59-2

Молекулярная масса

1239.42 g/mol

1526.74 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Buserelin

Buserelin is a potent GnRH agonist: after an initial stimulatory surge ('flare'), continuous receptor occupancy causes downregulation and thereby suppression of LH, FSH and the downstream sex hormones.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Buserelin	Linaclotid
Германия	Рецептурный	Рецептурный
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Buserelin and Linaclotid?: Buserelin is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Buserelin or Linaclotid?: The highest available evidence level is "РКИ на людях" for Buserelin and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Buserelin and Linaclotid in Germany and the United States?: Германия: Buserelin — Рецептурный, Linaclotid — Рецептурный. США: Buserelin — Не одобрено, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Buserelin

Linaclotid

Германия

Рецептурный

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Buserelin and Linaclotid?

Buserelin is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Buserelin: Buserelin is a synthetic GnRH agonist (including as a nasal spray). It is used in endometriosis, hormone-dependent prostate cancer and assisted reproduction; approved in Europe (Suprefact), not in the US. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Buserelin or Linaclotid?

The highest available evidence level is "РКИ на людях" for Buserelin and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Buserelin and Linaclotid in Germany and the United States?

Германия: Buserelin — Рецептурный, Linaclotid — Рецептурный. США: Buserelin — Не одобрено, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.